Skip to main content
Premium Trial:

Request an Annual Quote

Lilly Adds $50M to INGEN Endowment

NEW YORK, April 7 - The Lilly Endowment today awarded $50 million to the Indiana Genomics Initiative (INGEN), adding to the $105 million it provided to launch the program at Indiana University in December 2000.

 

Craig Brater, dean of the IU School of Medicine, indicated that the new grant would be used to increase research space for the INGEN initiative on IU's Indianapolis campus. "The individuals we are recruiting are highly sought after and one of the deciding issues for any good researcher is the quality and amount of lab space available to them," said Brater. The School of Medicine recently completed a space analysis showing that 345,000 square feet of new laboratory space is needed to house INGEN projects

 

INGEN programs on the IU Bloomington campus will also benefit from the grant, which will "allow us to expand and outfit the new Multidisciplinary Science Building on the Bloomington campus to accommodate INGEN-related research programs and personnel," said Kumble Subbaswamy, dean of the College of Arts and Sciences in Bloomington, who estimates the campus needs an additional 160,000 square feet of laboratory space.

 

The initial INGEN grant from the Lilly Endowment brought 23 new researchers to the Indianapolis and Bloomington campuses of IU, and the university estimates that the initiative has helped attract an additional $32 million in new research grants, with $36 million more in grant applications currently under review.

 

Analysis conducted in 2000 by the Battelle Memorial Institute projected INGEN would create 500 basic genomics jobs in Indiana by 2005 -- 74 within the university, 127 in private sector biotechnology firms, and nearly 300 throughout the rest of the state's economy.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more